New Corporate Adviser
May 16 2008 - 3:00AM
UK Regulatory
RNS Number : 6023U
Medicsight Plc
16 May 2008
Press Release 16 May 2008
Medicsight PLC
("Medicsight" or "the Company")
Appointment of Corporate Adviser
Appointment of NM Rothschild & Sons Limited as corporate adviser
Medicsight PLC (AIM:MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which
assists in the early detection and diagnosis of disease, is pleased to announce the appointment of NM Rothschild & Sons Limited as corporate
adviser.
As stated in the Company's AIM Admission document, one of Medicsight's objectives over the next one to two years is to seek strategic
merger and acquisition opportunities in order to introduce additional products into the Company's portfolio. Rothschild has been appointed
to offer independent advice and help develop corporate opportunities.
Tim Paterson-Brown, Chairman of Medicsight, said: "Rothschild brings us independent and strategic advice with the benefit of a strong
healthcare team. We look forward to a long-term and successful working relationship with Rothschild."
- ends -
For further information:
Medicsight PLC
David Sumner Tel: +44 (0)20 7605 7950
www.medicsight.com
Nomura Code Securities Limited
Juliet Thompson, Managing Director Tel: +44 (0)20 7776 1200
Jon Senior www.nomuracode.com
NM Rothschild & Sons Limited
Hedley Goldberg, Managing Director Tel: +44 (0)20 7280 5000
www.rothschild.com
Media enquiries:
Abchurch Tel: +44 (0) 20 7398 7700
Heather Salmond Tel: +44 (0) 20 7398 7704
heather.salmond@abchurch-group.com
Stephanie Cuthbert / Simone Alves Tel: +44 (0) 20 7398 7718
stephanie.cuthbert@abchurch-group.com www.abchurch-group.com
Notes to editors
Medicsight PLC is a UK headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software
for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the
colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's
computer-aided detection (CAD) software has been validated using one of the world's largest and most population diverse databases of
verified patient CT scan data. Medicsight's ColonCAD* and LungCAD* software products are seamlessly integrated with the advanced 3D
visualisation workstations of several industry-leading imaging equipment partners.
About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing
challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations
generate as many as 1000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due
to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious
regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This is
critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful
treatment and a positive therapeutic outcome.
About Medicsight's CAD software
Medicsight's ColonCAD* and LungCAD* software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically
highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such
as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.
Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The
integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of
demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users
to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.
Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product
related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product
development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to
develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be
validated to the highest possible standards.
About ACRIN 6664
The preliminary results of the National US Computerised Tomography (CT) Colonography Trial (ACRIN study 6664), released on 28 September,
demonstrated convincingly that CT colonography is at least as sensitive and specific as conventional optical colonoscopy in detecting
adenomas of 1 cm diameter or larger. A few days later another major study was published in the prestigious New England Journal of Medicine
with a similar outcome. These compelling results from two large well-controlled studies are expected to lead to widespread adoption of CT
colonography (also known as virtual colonoscopy) as routine primary screening for colorectal cancer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDELFFVEBBBBF
Medicsight (LSE:MDST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medicsight (LSE:MDST)
Historical Stock Chart
From Jul 2023 to Jul 2024
